UBS Group Initiates Coverage on Summit Therapeutics (NASDAQ:SMMT)
Stock analysts at UBS Group started coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. UBS Group’s target price indicates a potential upside of 32.63% from the stock’s previous […]
More Stories
Fauci Deputy Who Declined COVID-19 Vaccine Feared Retaliation: Emails
By Zachary Stieber A top government doctor who declined to receive a COVID-19 vaccine in 2021 was worried he would...
20+ SEO Checklist For Blog Posts: Read Before Publishing
You wrote a fantastic blog. What’s next? Publishing blogs without optimizing them for SEO is like starting a shop without...
US Military Blockade on Iranian Ports Goes Into Effect, Maritime Group Says
By Jack Phillips A scheduled U.S. naval blockade of the Strait of Hormuz and nearby waters started at 10 a.m....
Who is Jonathan Joly? Age, Marriage, and Net Worth in 2026
If you like to scroll on social media, the chances of you witnessing Jonathan Joly are high. Are you also...
Rory McIlroy Wins Back-to-Back Masters Titles to Join Jack Nicklaus, Nick Faldo, and Tiger Woods
By The Associated Press AUGUSTA, Ga.—Rory McIlroy joined more elite company Sunday at the Masters when he pulled away with...
At Least 30 Dead in Stampede at Haiti’s Historic Laferriere Citadel
By Reuters At least 30 people were killed on Saturday in a stampede in the northern countryside of Haiti, authorities...